NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viatris Inc.

NEW YORK CITY, NY / ACCESS Newswire / March 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Shares of Viatris Inc. VTRS slid 2.81% to $8.98 Thursday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 1.39% to 5,521.52 and Dow ...

The investigation focuses on the propriety of Viatris' disclosures to its investors about the FDA's inspections of the company's manufacturing facility in Indore, India.

We recently published an article titled Why These 15 Large-Cap Stocks Are Plunging So Far In 2025. In this article, we are ...

Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its ...

Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. See why I ...

Barclays 27th Annual Global Healthcare Conference Call March 11, 2025 2:00 PM ETCompany ParticipantsScott Smith - Chief ...

Viatris (VTRS, Financials) shares dropped about 15% in pre-market trading after the company reported weaker-than-expected fourth-quarter results and issued a 2025 outlook below analyst expectations.

Viatris forecast annual revenue and profit below Wall Street estimates on Thursday, mainly due to a worse-than-feared hit to sales from import restrictions on the drugmaker's manufacturing plant in ...

Viatris launches review, plans share buybacks. CEO outlines strategy for cost structure and remediation efforts.

Shares of Viatris Inc. VTRS slipped 1.07% to $9.24 Wednesday, on what proved to be an all-around mixed trading session for ...